Craniosynostosis — a condition usually identified in infancy where the bones in a baby’s skull join together prematurely — led…
Lindsey Shapiro, PhD
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lindsey Shapiro, PhD
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate…
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise…
CHOLESTASIS
NewsFDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat…
FATTY LIVER DISEASE
NewsGLP-1 agonists linked to lower risk of complications in MASLD, MASH
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis…
The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health…
FATTY LIVER DISEASE
NewsPhase 3 trial of lanifibranor for MASH completes enrollment
Enrollment is complete for a Phase 3 clinical trial testing lanifibranor in people with metabolic dysfunction-associated steatohepatitis (MASH) — a…
Six months of treatment with Kezar Life Sciences‘ candidate zetomipzomib led to biochemical disease remission for adults with treatment-resistant…
CHOLANGITIS
NewsNebokitug shows sustained benefits for moderate, advanced PSC
A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events…
ALAGILLE SYNDROME
NewsLivmarli approved in Japan as itching treatment for Alagille, PFIC
Livmarli (maralixibat) has been approved in Japan for the treatment of itching in people with Alagille syndrome and…